Clinical Trials Logo

Clinical Trial Summary

Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.


Clinical Trial Description

Subjects will have painful primary or post-operative intermetatarsal neuroma. Each subject will be randomly allocated to receive either ALGRX 4975 or placebo in a 1:1 ratio. Study drug or placebo will be injected into the intermetatarsal space containing a painful neuroma. Subjects will complete weekly assessments for the Average Foot Pain Severity, the 7 Interference Items of the BPI, and the number of analgesic units taken. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.

Plasma concentrations will be assessed pre-dose and post dose at 5, 10, 15, 20, 30, and 45 min and at 1, 1.5, 2, 2.5, 3 and 4 hours.

Safety will be assessed at baseline and during the study with adverse events (all visits), vital signs (Visit 2 pre and post-injection and Visit 3 or at early termination), and laboratory assessments (hematology, chemistry, urinalysis) and ECG (Screening and Visit 3 or at early termination). The injection site will be examined and assessed by a 6-point scale for erythema, edema, and hemorrhage before the injection and at 1, 2 and 4 hours after the injection. A pain on injection NRS will be assessed immediately post- injection at 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after study drug administration. A sensory examination of the foot will be performed before the injection and 4 hours after the injection and at the completion of the study. If a subject has injection pain, the foot may be wrapped in ice for up to 20 minutes, analgesic medication may be provided. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00130962
Study type Interventional
Source AlgoRx Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date September 2004
Completion date February 2006

See also
  Status Clinical Trial Phase
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Recruiting NCT05008185 - Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
Completed NCT02316262 - Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation N/A
Completed NCT02205385 - Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation N/A
Completed NCT04931056 - A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.
Completed NCT01632709 - Pathophysiology of Post Amputation Pain Phase 4
Completed NCT02528266 - Surgical Treatment of Symptomatic Neuroma "Stop Neuroma" N/A
Withdrawn NCT01374191 - Botulinum Toxin Type A for Neuroma Pain Phase 2
Enrolling by invitation NCT06164392 - Evaluation of Neuroma Perfusion With Indocyanine Green Fluorescence Angiography Phase 4
Completed NCT03484429 - Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain N/A
Completed NCT03051113 - Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations
Completed NCT02993276 - Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma